Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs

Annals of Neurology

Volumn 54, Issue 2, 2003, Pages 235-238

  Perry, Elaine K ^a   Kilford, Linda ^c   Lees, Andrew J ^b   Burn, David J ^a   Perry, Robert H ^a  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; AMYLOID BETA PROTEIN; ANTIPARKINSON AGENT; BENZATROPINE; CEVIMELINE; CHOLINESTERASE INHIBITOR; GALANTAMINE; IMIPRAMINE; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC RECEPTOR BLOCKING AGENT; ORPHENADRINE; OXYBUTYNIN; RIVASTIGMINE; TALSACLIDINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIHEXYPHENIDYL;

AGED; ALZHEIMER DISEASE; ANTICHOLINERGIC EFFECT; ARTICLE; BLADDER DYSFUNCTION; CELL DENSITY; CHOLINERGIC RECEPTOR BLOCKING; CHRONICITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG POTENCY; ELDERLY CARE; FEMALE; HUMAN; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; NEUROFIBRILLARY TANGLE; PARKINSON DISEASE; PRIORITY JOURNAL; SENILE PLAQUE; STATISTICAL SIGNIFICANCE; TREMOR;

EID: 0042867233     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10639     Document Type: Article

References (20)

1. Farlow M. Do cholinesterase inhibitors slow progression of Alzheimer's disease? Int J Clin Pract Suppl 2002;127:37-44.
2. Hock C, Maddalena A, Heuser I, et al. Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid beta-peptide in patients with Alzheimer's disease. Ann N Y Acad Sci 2000;920:285-291.
3. Nitsch RM, Deng M, Tennis M, et al. The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 2000;48:913-918.
4. Beach TG, Kuo YM, Schwab C, et al. Reduction of cortical amyloid beta levels in guinea pig brain after systemic administration of physostigmine. Neurosci Lett 2001;310:21-24.
5. Nordberg A, Hellstrom-Lindahl E, Lee M, et al. Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). J Neurochem 2002;81:655-658.
6. Perry E, Martin-Ruiz C, Lee M, et al. Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur J Pharmacol 2000;393:215-222.
7. Beach TG, Walker DG, Potter PE, et al. Reduction of cerebrospinal fluid amyloid beta after systemic administration of MI muscarinic agonists. Brain Res 2001;90:220-223.
8. Lin L, Georgievska B, Mattsson A, Isacson O. Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation. Proc Natl Acad Sci USA 1999;96:12108-12113.
9. Sadot E, Gurwitz D, Barg J, et al. Activation of m1 muscarinic acetylcholine receptor regulates phosphorylation in transfected PC12 cells. J Neurochem 1996;66:877-880.
10. Forlenza OV, Spink JM, Dayanandan R, et al. Muscarinic agonists reduce τ phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons. J Neural Transm 2000;107:1201-1212.
11. McKeith IG. Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia. Neurol Clin 2000;18:865-902.
12. Anderton BH. Ageing of the brain. Mech Ageing Dev 2002;123:811-817.
13. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathological study of 100 cases of Parkinson's disease. Arch Neurol 1993;50:140-148.
14. Ulrich J, Johannson-Locher G, Seiler WO, Stahelin HB. Does smoking protect from Alzheimer's disease? Alzheimer-type changes in 301 unselected brains from patients with known smoking history. Acta Neuropathol (Berl) 1997;94:450-454.
15. Starkstein SE, Robinson RG. Mood disorders in neurodegenerative diseases. Semin Clin Neuropsychiatry 1996;1:272-281.
16. Eckols K, Bymaster FP, Mitch CH, et al. The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from Chinese hamster ovary-m1 cells. Life Sci 1995;57:1183-1190
17. Muller DM, Mendla K, Farber SA, Nitsch RM. Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain. Life Sci 1997;60:985-991.
18. Rossner S, Ueberham U, Schliebs R, et al. The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signalling. Prog Neurobiol 1998;56:541-569.
19. Genis I, Fisher A, Michaelson DM. Site-specific dephosphorylation of τ of apolipoprotein E-deficient and control mice by M1 muscarinic agonist treatment. J Neurochem 1999;72:206-213.
20. Haring R, Gurwitz D, Barg J, et al. NGF promotes amyloid precursor protein secretion via muscarinic receptor activation. Biochem Biophys Res Commun 1995;213:15-23.